Combined Recombinant Human Erythropoietin-Blood Letting Strategy for Treating Anemia and Iron Overload in Hemodialysis Patients
| Autor: | Kapetanaki A, D Koutsicos, Varsou-Papadimitriou E, Tzanatou-Exarchou H, Basil Agroyannis, H Yatzidis |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
medicine.medical_specialty Time Factors Blood transfusion Anemia medicine.medical_treatment 030232 urology & nephrology Biomedical Engineering Refractory anemia Medicine (miscellaneous) Bioengineering 030204 cardiovascular system & hematology law.invention Biomaterials 03 medical and health sciences 0302 clinical medicine Renal Dialysis law Humans Medicine Blood Transfusion Erythropoietin Hemochromatosis Bloodletting business.industry Anemia Refractory General Medicine medicine.disease Combined Modality Therapy Recombinant Proteins Surgery Recombinant DNA Kidney Failure Chronic Blood letting Female Hemodialysis business medicine.drug |
| Zdroj: | The International Journal of Artificial Organs. 14:403-406 |
| ISSN: | 1724-6040 0391-3988 |
| DOI: | 10.1177/039139889101400704 |
| Popis: | We studied the feasibility of treating refractory anemia and post-transfusional serious hemochromatosis in a patient undergoing hemodialysis (3x4 h weekly) for fourteen years, with recombinant human erythropoietin (r-HuEPO) associated with blood-letting. Blood transfusion previously received by the patient at a rate of two units of packed red cells every month for nine years was stopped and r-HuEPO (80 U/kg b.w.) was administered i.v. at the end of each hemodialysis. When Hct increased over 30%, approximately 40 ml of blood was removed per hemodialysis session in an attempt to accelerate iron loss. Excellent control of anemia and hemochromatosis was achieved after seven months of treatment. The patient's general condition and skin pigmentation were significantly improved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|